[Overall treatment of vascular epilepsy]

C Viteri1, A Oliveros, E Urrestarazu

  • 1Departamento de Neurología y Neurocirugía, Clínica Universitaria de la Universidad de Navarra, Pamplona, España.

Revista De Neurologia
|March 14, 2000
PubMed

Insights

Cerebrovascular disease can cause epilepsy, with hemorrhagic strokes and cortical involvement increasing risk. Acute seizures are treatable, but long-term epilepsy prevention with antiepileptic drugs remains uncertain.

Area of Science:

  • Neurology
  • Vascular Neurology
  • Epileptology

Context:

  • Cerebrovascular disease presents acutely with ischemic or hemorrhagic events.
  • Epileptic seizures can occur during the acute phase or develop as a later epileptic syndrome.
  • Status epilepticus is a rare but possible complication at any stage of cerebrovascular disease.

Purpose:

  • To explore the relationship between cerebrovascular disease and epilepsy.
  • To discuss the risk factors for developing seizures after a stroke.
  • To review current management strategies for seizures and status epilepticus in cerebrovascular disease patients.

Summary:

  • The occurrence of acute epileptic crises or an epileptic syndrome post-stroke depends on the vascular accident's nature, with hemorrhagic lesions and cortical involvement posing higher risks.
  • Acute seizures can be managed with benzodiazepines or rapid-acting antiepileptic drugs, potentially requiring parenteral administration.
  • The efficacy of prolonged prophylactic antiepileptic treatment in preventing future epileptic syndromes is not yet established.
  • Management of status epilepticus is standardized, but patient-specific factors like age and comorbidities must be considered.
  • Treatment decisions for vascular epilepsy necessitate evaluating drug pharmacokinetics and interactions with concurrent medical conditions.

Impact:

  • Provides insights into the complex interplay between cerebrovascular events and epilepsy.
  • Highlights the need for individualized treatment approaches in managing seizures associated with stroke.
  • Informs clinical practice regarding the uncertain role of prophylactic antiepileptic therapy.
  • Emphasizes the importance of considering drug interactions in patients with multiple health issues.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.